Astec Lifescienc (ASTEC)

FairStock Score: 6/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 32.88% shows revenue traction in a challenging agrochemical environment
• Promoter holding of 71.97% aligns controlling shareholders with minority investors
• Piotroski F-Score of 6/9 suggests the company is not in acute financial distress
• Book value of ₹131.57 provides some asset backing despite negative earnings

Concerns

• Latest quarter net loss of ₹16 Cr and P/E of 0.00 indicate no earnings support for the stock price
• ROE of -30.71% and ROCE of -12.86% show capital is being destroyed, not compounded
• Price-to-book of 5.58 is far too rich for a business with negative returns
• Debt/Equity of 0.89 adds balance sheet risk when operating profits are absent

AI Analysis

Let me start with what I understand: Astec Lifescienc sells pesticides and agrochemicals. In farming-linked businesses, a cheap product with reliable distribution can be valuable, but the numbers here do not yet support that. The company is losing money—latest quarter sales of ₹125 Cr produced a net loss of ₹16 Cr. Annual returns are deeply negative: ROE is -30.71% and ROCE is -12.86%. A business that earns no returns on equity or capital, while carrying Debt/Equity of 0.89, is not a compounding machine; it is a consumption machine. The P/E being 0.00 is not a bargain signal—it is an earnings absence signal. Paying ₹733.85 per share, or 5.58 times book value of ₹131.57, for such negative profitability is the opposite of margin of safety. The 32.88% sales growth and claimed 66.30% profit growth sound good, but the profit figure is suspect in a company that just posted a quarterly loss. Growth is only worth something if it eventually produces earnings. Promoter holding of 71.97% is reassuring, and the Piotroski F-Score of 6/9 suggests financial distress is not extreme, but neither changes the arithmetic. The 52-week range shows the stock has fallen from ₹941.75 to ₹733.85; that may tempt a bargain hunter, but price decline is not value. I would need to see meaningful margin restoration, positive quarterly profit, and deleveraging before I can call this a turnaround. Until then, the risk/reward is poor. No dividend, no earnings, negative returns on capital, and a rich price-to-book ratio. This is a pass for a value investor.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer